<!DOCTYPE html>
<html>
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" type="text/css" href="css/style-manual.css">
    <link rel="stylesheet" href="https://www.w3schools.com/w3css/4/w3.css">
    <script src="js/script.js"></script>
</head>
<body>
<!--Faropen-------------------------------------------------------->
<div class="bodyDiv" id="idFaropen">
    <div class="w3-container w3-center w3-animate-left">
        <h2 class="mango">Faropen</h2>
    </div>
<b>Product Orientation & Presentation:</b><br>

<b>Need Assesment:</b><br>
ANTIBIOTIC RESISTANCE! is there any oral option...?<br>
Antibiotic resistance results in at least 7 lac annual deaths across the world which is expected to increase to 
1 crore by 20551. In Bangladesh, injectable Carbapenem is widely prescribed to face the challenges of 
antibiotic resistance. But some limitations and inconvenience may limit the optimum benefits of injectable 
Carbapenems, such as patient-inconvenience, need of skilled nurses, hospital stay and higher cost.<br>
Faropenem is a novel oral Carbapenem which is stable against all &#946;-lactamases and has the broadest 
anti-bacterial spectrum with strong anti-bacterial activity against both Gram-positive and Gram-negative bacteria
<br>

<b>Brand Name:</b><br>
Faropen(The first Oral Carbapenem)
<br><br>

<b>Generic & Strength:</b><br>
Faropen 150 mg Tablet: Faropenem 150 mg<br>
Faropen 200 mg Tablet: Faropenem 200 mg
<br><br>
	
<b>Dosage Form:</b><br>
Tablet
<br><br>
	
<b>Therapeutic Class:</b><br>
Beta-Lactam Antibiotic
<br><br>

<b>Sub Therapeutic class:</b><br>
<br><br>

<b>Commercial Pack:</b><br>
2 x 6's
<br><br>

<b>Price(MRP):</b><br>
70.00 Bdt/Tab
<br><br>

<b>Flavour:</b><br>
<br><br>

<b>Indication:</b><br>
<li> URTIs:</li>
pharyngitis, tonsillitis.<br>
<li> LRTIs:</li>
acute bronchitis, pneumonia, pulmonary suppuration.<br>
<li> ENT infections:</li>
otitis externa, tympanitis, sinusitis.<br>
<li> SSSIs:</li>
pustular acne, folliculitis, contagious impetigo, erysipelas, lymphangitis, suppurative nail inflammation, subcutaneous abscess, hidradenitis (sweat gland inflammation), infective sebaceous cyst, chronic pyoderma, secondary infection of external wounds or surgical wounds.<br>
<li> UTIs:</li>
pyelonephritis, cystitis, prostatitis, seminal gland inflammation.<br>
<li> Gynecological infections:</li>
adnexitis, bartholin gland inflammation.
<br><br>

<b>Dosage & Administration:</b><br>
1 Tablet 3 Times Daily for 7-14 Days.<br>

<li> URTIs:</li>
150mg-200mg t.i.d.<br>

<li> SSTIs:</li>
150mg-200mg t.i.d.<br>

<li> LRTIs:</li>
200mg-300mg t.i.d.<br>

<li> UTIs:</li>
200mg-300mg t.i.d.<br>

<li> ENT Infection:</li>
200mg-300mg t.i.d.<br>
<br><br>

<b>Pregnancy:</b><br>
Pregnancy: Safety during pregnancy has not been established.
<br><br>

<b>Lactation:</b><br>
Faropenem should not be given to nursing mother as it is excreted in human milk
<br><br>

<b>Children:</b><br>
Safety in children below 18 years of age has not been established
<br><br>

<b>Brand Name Justification:</b><br>
<b>Farope</b>nem= Faropen
<br><br>

<b>Brand Slogan:</b><br>
<br><br>

<b>Key Selling Points:</b><br>
No IV-associated side effects<br>
No trained nurse required<br>
Cost effective treatment
<br><br>

<b>Target Doctor:</b><br>
<br>

<b>Objective:</b><br>
<br><br>

<b>Action:</b><br>
<br><br>

<b><u>Mode of Action:</u></b><br>

<table class="table2">
<tbody>
    <tr>
       <td>
Faropenem
	   </td>
    </tr>
	
    <tr>
       <td>
<b>&#8681;</b>
	   </td>
    </tr>    
	
	<tr>
       <td>
Penicillin binding protein(PBP)
	   </td>
    </tr>    
	<tr>
       <td>
<b>&#8681;</b>
	   </td>
    </tr>    
	<tr>
       <td>
Inhibits cross-linkage of the peptidoglycan
	   </td>
    </tr>    
	<tr>
       <td>
<b>&#8681;</b>
	   </td>
    </tr>    
	<tr>
       <td>
Destroys bacterial Cell wall
	   </td>
    </tr>    
	<tr>
       <td>
<b>&#8681;</b>
	   </td>
    </tr>
	
    <tr>
	   <td>
Bacterial cell death
	   </td>
    </tr>
</tbody>
</table>

<b>Side effects:</b><br>
<br><br>

<b>Contraindication:</b><br>
<br><br>

<b>Precautions and warnings:</b><br>
<br><br>

<b>Interaction:</b><br>
<br><br>
Clinical success rates
Bronchitis
UTI
Pharyngitis
Tonsillitis
Pneumonia
100%
>90% URTI, Otitis Media

Bacteriological eradication rates: 100%
Staphylococcus aureus
Streptococcus pneumoniae
Streptococcus pyogenes
Enterococcus faecalis
Moraxella catarrhalis
Escherichia coli
Haemophilus influenzae

200 mg 3 times daily, it can be increased to 300 mg
3 times daily in UTI, LRTI', ENT infections

150 mg 3 times daily, it can be increased to 200 mg
3 times daily in URTI', SSSI

New antibiotic offers least resistance

Oral carbapenem ensures patients 
compliance

Pouch pack provides extra protection<br><br>


<b>Faropen Model Detailing</b><br>

স্যার<br>
Good morning আপনি জানেন অ্যান্টিবায়োটিক রেজিস্টেন্স ব্যাকটেরিয়াল ইনফেকশন চিকিৎসায়
খুবই concerning issue হয়ে দাড়িয়েছে। প্রচলিত অ্যান্টিবায়োটিকগুলো রেজিস্টেন্স হয়ে যাচ্ছে,
যার জন্য Carbapenem গ্রুপের অ্যান্টিবায়োটিককে বর্তমানে শক্তিশালী অ্যান্টিবায়োটিক মনে
করে থাকেন । কিন্তু এই Carbapenem অ্যান্টিবায়োটিকগুলো ইনজেকটেবল হিসেবে এভেইলেবল
হওয়ায় patient compliant না। তাই একটি Oral Carbapenem হলে কেমন হয়, স্যার?
<br>
তাই Navana Pharma introduces, Faropen যার generic, Faropenem.<br>
The first oral Carbapenem.<br>
<b>Faropen</b> যা modified form of Meropenem এবং এতে tetrahydrofuran ring থাকার কারণে এই drug stomach এ stable. <b>Faropen</b> ব্যাকটেরিয়ার cell wall synthesis inhibit
করার মাধ্যমে ব্যাকটেরিয়াকে destroy করে।
<br>

স্যার,<br>
Pneumococci ব্যাকটেরিয়ার ক্ষেত্রে <b>Faropen</b> এর MIC90 0.03 mg / L যেখানে Amoxicillin
এবং Cefuroxime উভয়ের MIC90 0.06mg / L. এমনকি H. Influenzae এর ক্ষেত্রে <b>Faropen</b> এর MIC90 1mg/L যেখানে Amoxicillin এর MIC90 16 mg/L এবং Cefuroxime এর MIC90 4 mg/L.
<br>

স্যার,<br>
LRTI & URTI এর ক্ষেত্রে <b>Faropen</b> এর Success rate 100%. Post-surgical pathogen এর ক্ষেত্রেও <b>Faropen</b> এর eradication rate 100%, তাই switch therapy-তে Meropenem থেকে Feropenem এ switch করাটাই best choice.<br>

So, <b>Faropen</b> ensures<br>

* 100% eradication rate of surgical pathogens ensures complete cure.<br>
* New antibiotic offers resistance-free treatment in RTIS.<br>
* Oral Carbapenem ensures patient's compliance.<br>
* Pouch pack provides extra protection.<br><br>
Note: MIC90-Minimum Inhibitory Concentration 90%<br><br>

  <h4>Features | Advantages | Benefits</h4>
  <table class="t01">
    <tr>
      <th>Features</th>
      <th>Advantages</th>
      <th>Benefits</th>
    </tr>
    <tr>
      <td>Provided with Poly Pouch-Pack</td>
      <td>Prevents degradation from moisture</td>
      <td>Ensures consistent efficacy till the shelf life</td>
    </tr>
  </table>

    <h4>Short Detailing</h4>
  <p>
Dear Doctor,<br>
Carbapenem is one of the most preferable antibiotics nowadays for its high efficacy & safety profile. However, it was available only in an injectable form which was not convenient.<br>
For this reason, Navana Pharma introduced the most effective & powerful Carbapenem group antibiotic in oral form as Faropen (Faropenem).<br>
Navana Pharma has come up with the solution and is going to introduce the first oral carbapenem,<br>
• 100% eradication rate of surgical pathogens ensures complete cure<br>
• New antibiotic offers resistance free treatment in RTIs<br>
• Oral Carbapenem ensures patients compliance<br>
• Pouch pack provides extra protection<br>
• Low price
  </p>


  <div class="spin-block">
    <h4>SPIN MODEL (Respiratory)</h4>
    <p><strong>Situation:</strong> What % of patients come to you with bacterial infections like RTIs, UTIs, and ENT infection?</p>
    <p><strong>Problem:</strong> Does antibiotic resistance lead to more death annually?</p>
    <p><strong>Implications:</strong> Are these complications making the patients disable and hampering the patient's quality of life?</p>
    <p><strong>Needs:</strong> Can we offer a new oral carbapenem that offers resistance-free with 100% efficacy?</p>
  </div>

  <div class="spin-block">
    <h4>SPIN MODEL (Ortho/Surgery)</h4>
    <p><strong>Situation:</strong> What % of patients are hospitalized for surgical issue?</p>
    <p><strong>Problem:</strong> Does injectable Carbapenem lead to longer treatment & higher cost?</p>
    <p><strong>Implications:</strong> Is this longer duration of injectable treatment & higher cost making patients dissatisfied?</p>
    <p><strong>Needs:</strong> Can we offer a new oral carbapenem that reduces the durability of taking injection & treatment cost?</p>
  </div>





<b>Frequently Asked Questions (FAQ)</b><br>
<b class="FQ"> 1. Who approved the Faropenem as the novel oral Carbapenem & why?</b><br>
Ans: Faropenem is approved in Japan & India as a novel oral Carbapenem because it is active against Beta-Lactamase and has a low propensity for bacterial resistance.
<br><br>

<b class="FQ"> 2. How is Faropenem orally active?</b><br>
Ans: Faropenem is orally active due to having a Tetrahydrofuran ring in its structure. This ring makes Faropenem stable in the stomach.
<br><br>

<b class="FQ"> 3. What will be the duration of treatment?</b><br>
Ans: The duration of treatment is 7 to 14 days and the duration depends on the severity of the infections.
<br><br>

<b class="FQ"> 4. Meropenem should be taken 500 mg/1 gm three times a day but Faropenem should be taken 150 mg/200 mg three times a day- Why?</b><br>
Ans: Feropenem has a lesser MIC90 value than Meropenem. That's why Faropenem is effective in lower strength.
<br><br>

<b class="FQ"> 5. Is Faropenem safe for pregnant women and lactating mothers?</b><br>
Ans: There is no safety data available for pregnant or lactating mothers. So, Faropenem should be avoided during pregnancy and lactation. 
<br><br>

<b class="FQ"> 6. Can Faropenem be used as a first-line treatment for bacterial infection? </b><br>
Ans: Yes, Faropenem can be used. However, the dose should be completed according to the dosage guidelines to prevent bacterial resistance. 
<br><br>

<b class="FQ">Shows more potency than Amoxicillin & Cefuroxime in LRTIs</b>
    <ul>
        <li><strong>MIC<sub>90</sub> (mg/L)</strong></li>
         Susceptibility of Pneumococci(474 susceptible strains)<br>
        <li>Faropenem: 0.03</li>
        <li>Amoxicillin: 0.06</li>
        <li>Cefuroxime: 0.06</li>

        <li><strong>MIC<sub>90</sub> (mg/L)</strong></li>
        Susceptibility of H. influenzae<br>
        <li>Faropenem: 1</li>
        <li>Amoxicillin: 16</li>
        <li>Cefuroxime: 4</li>
    </ul>
    <p><strong>Provides excellent bactericidal activity</strong></p>

    <b class="FQ">Clinical success rates <strong style="color: brown;">100%</strong></b>
<ul>
    <li>Bronchitis</li>
    <li>UTI</li>
    <li>Pharyngitis</li>
    <li>Tonsillitis</li>
    <li>Pneumonia</li>
    <li>SSSS</li>
    <li>&gt;90% URTi, Otitis Media</li>
</ul>

<b class="FQ">Bacteriological eradication rates <strong style="color: brown;">100%</strong></b>
<ul>
    <li>Staphylococcus aureus</li>
    <li>Streptococcus pneumoniae</li>
    <li>Streptococcus pyogenes</li>
    <li>Enterococcus faecalis</li>
    <li>Moraxella catarrhalis</li>
    <li>Escherichia coli</li>
    <li>Haemophilus influenzae</li>
</ul>
<p class="FQ">SSSS</p>
Staphylococcal Scalded Skin Syndrome.
<br><br>


<b>Abridged prescribing information:</b><br>
<b>Composition:</b><br>
Faropen 150 Tablet: Each film-coated tablet contains Faropenem Sodium INN equivalent to Faropenem 150 mg.<br>

<b>Pharmacology:</b><br>
Like other beta-lactam antibiotics, Faropenem acts by inhibiting the synthesis of bacterial cell wall. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell wall of gram-positive bacteria. It does this by binding to and competitively inhibiting the transpeptidase enzyme used by bacteria to cross-link the peptide (D-alanyl-alanine) used in peptidogylcan synthesis.<br>

<b>Indications:</b><br>
Faropenem is indicated for treatment of the following infections:<br>
* Urinary Tract Infections:<br>
Pyelonephritis, Cystitis, Prostatitis, Seminal Gland Inflammation.<br>
* Upper Respiratory Tract Infections:<br>
Pharyngitis, Tonsillitis.<br>
* Lower Respiratory Tract Infections:<br>
Acute Bronchitis, Pneumonia, Pulmonary Suppuration.<br>
* Ear, Nose and Throat (ENT) Infections:<br>
Otitis Externa, Tympanitis, Sinusitis.<br> 
* Skin and Skin Structure Infections:<br>
Pustular Acne, Folliculitis, Contagious Impetigo, Erysipelas, Lymphangitis, Suppurative Nail Inflammation, Subcutaneous Abscess, Hidradenitis (Sweat Gland Inflammation), Infective Sebaceous Cyst, Chronic Pyoderma, Secondary infection of external wounds or surgical wound. without regarding food which means before or after meal or as directed by the physician.<br>

<b>Contraindication:</b><br>
Faropenem is contraindicated in patients with known hypersensitivity to any of the components of this drug or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams.<br>

<b>Warnings & Precautions:</b><br>
Faropenem should be administered with caution in the followings: Patients with a past history of hypersensitivity to penicillin, cephem or carbapenem drugs. Patients with a family history of atopy. The dosage should be reduced or the interval between doses should be increased in patients with renal impairment, Geriatric patients.<br>

<b>Side Effects:</b><br>
Faropenem is generally well-tolerated. The most frequently reported side effects are diarrhoea, abdominal pain, nausea and rash.<br>

<b>Use in Pregnancy and Lactation:</b><br>
Safety during pregnancy has not been established. In pregnant women or expectant mothers, the medicine should be given only if the benefits of the treatment are greater than the risks involved. Faropenem is excreted in human milk. Therefore, Faropenem should be given to nursing mothers only if the benefits outweigh the risks.<br>

<b>Use in Children & Adolescents:</b><br>
Safety in children below 18 years of age has not been established.<br>

<b>Drug Interaction:</b><br>
Imipenem and Cilastatin sodium combination:<br>
It has been reported that in animal studies (rat), the concentration of Faropenem in the blood increases. It is due to the obstruction of metabolic fermentation by cilastatin.<br>
Furosemide:<br>
It has been reported in animal studies (dog) that the kidney toxicity of Faropenem increases.<br>
Sodium Valproate:<br>
It has been reported that due to concomitant use with Carbapenem drugs (Meropenem and Imipenem-Cilastatin Sodium), the concentration of Valproic acid in the blood reduces and there is a recurrence of epileptic fits.<br>

<b>Overdosage:</b><br>
No specific informaion is available on the treatment of overdosage with Faropenem. In overdose, Faropenem should be discontinued & general supportive treatment should be given until renal elimination takes place.<br>

<b>Storage:</b><br>
Store below 25°C, away from light and in a dry place. Keep all medicines out of the reach of children.<br>

<b>Packing:</b><br>Faropen 150 Tablet: Each box contains 2 x 6 tablets in Alu-Alu blister pack within Alu-Alu sachet and an insert.<br><br>


    <div class="link-btn" onclick="window.open('https://drive.google.com/file/d/1ogdGvbynlSnY3KSwGYlLi10McVpeh5Cf/view?usp=drivesdk', '_blank')">Faropen PPT.pdf</div>    
	<div class="link-btn" onclick="window.open('https://drive.google.com/file/d/1wrdDs0cDNLRBviLRqK1I56i7Ejuoxkns/view?usp=drivesdk', '_blank')">Faropen Launching Literature.pdf</div>    

</div>   
<footer>
    <p>© 2024 Md. Nurullah. All rights reserved.</p>
</footer>
<center><div class="ovalEnd">The End-Faropen</div></center><!--End Line---->
</body>
</html>